Proactive - Interviews for investors

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler talked with Proactive's Stephen Gunnion about the company’s recent milestone—the first human dose of its proprietary CAR-T cell therapy, HG-CT-1, for treating relapsed refractory acute myeloid leukemia (AML) in adults. This is a significant development in tackling one of the deadliest blood cancers, which has a low remission rate with current frontline therapies.

Sandler explained, “We are trying to cure a very deadly disease which is called acute myeloid leukemia... This is one of the worst blood cancers in existence.” He highlighted that only 30% of newly diagnosed patients respond to frontline therapies, leaving a significant need for more effective treatments.

The therapy uses third-generation chimeric antigen receptor (CAR) technology, which, according to Sandler, offers the same efficacy as the current second-generation CARs but with enhanced safety. The company is poised to accelerate its clinical trials, pending resource availability, with the potential to infuse patients every 14 days after the fourth patient.

With the first patient showing no adverse effects so far, Hemogenyx is hopeful about the progress of HG-CT-1 and is ready to scale up manufacturing as new patients are identified.

For more insightful interviews and the latest updates, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content.

#Hemogenyx #CAR_Therapy #HGCT1 #AML #CancerTreatment #Biotechnology #HealthcareInnovation #ClinicalTrials #BloodCancer #Investing

Lutris Pharma CEO Dr Noa Shelach talked with Proactive's Stephen Gunnion about the company's innovative approach to enhancing cancer treatment adherence through its lead asset, LUT014. The clinical-stage biopharmaceutical company, founded in 2016, aims to improve the effectiveness of anti-cancer therapies and patient quality of life by addressing severe dermatological side effects such as acneiform lesions, a common adverse reaction to EGF receptor inhibitors.

Shelach highlighted LUT014, a proprietary topical B-Raf inhibitor, designed to reduce dermal toxicities and improve treatment continuity. The company recently completed enrollment of 117 patients in a Phase 2 international trial for metastatic colorectal cancer, with promising results from a smaller Phase 1/2 study in breast cancer patients. However, the latter is not being actively pursued further.

In January 2025, Lutris Pharma secured $30 million in financing, led by Columbus Venture Partners and Pontifex Venture Capital, alongside Peregrine Ventures and Moon Fund. The funds will support advancing LUT014 through Phase 3 development, aiming for commercialization to help cancer patients maintain their treatment regimens.

Shelach noted the $1 billion market potential for LUT014, emphasizing that increased patient adherence to EGF receptor inhibitors could boost drug sales by 30%. Investors should watch for Phase 2 trial results expected in the first half of 2025, with Phase 3 trials planned to start by the end of the year.

Stay tuned to Proactive’s YouTube channel for more interviews with industry leaders. Don't forget to like, subscribe, and hit the notification bell to keep up with the latest insights.

#LutrisPharma #CancerTreatment #EGFRInhibitors #LUT014 #Biopharma #ClinicalTrials #Oncology #Investing #DermalToxicity #ColorectalCancer

NextEnergy Solar Fund Ltd (LSE:NESF) investment director and UK legal counsel Stephen Rosser talked with Proactive's Stephen Gunnion about the company's steady third-quarter performance and growth prospects underpinned by the UK's Clean Power 2030 plan. Rosser highlighted the successful completion of the third phase of NESF’s capital recycling program, including the sale of Staughton at a 21.5% premium, contributing to a total of £72.5 million capital recycled to date.

Despite less-than-optimal generating conditions due to adverse weather and grid outages, Rosser said NESF expects to maintain a cash cover of around 1.1 times for its full-year dividend target of 8.43p. He discussed ongoing strategies to address the share price discount, including advancing the fourth phase of the capital recycling program and continuing share buybacks. So far, NESF has repurchased over 12.5 million shares for approximately £10 million, aiming for a total buyback of £20 million.

Rosser expressed optimism about the UK's solar and energy storage landscape, noting opportunities from the Clean Power 2030 initiative, which targets 50GW of installed solar capacity by 2030. With a strong ESG track record, including over 2,700 tonnes of CO2 avoided since inception, NESF is focused on delivering shareholder value and capitalising on growth opportunities.

Stay tuned to Proactive's YouTube channel for more insightful interviews. Don’t forget to like this video, subscribe to our channel, and hit the notification bell for updates!

#NextEnergySolarFund #NESF #CleanPower2030 #SolarEnergy #ESGInvesting #ShareBuyback #CapitalGrowth #RenewableEnergy #DividendYield #ProactiveInvestors

Alt Resources PLC (AIM:ALTR) Director and CFO-elect James Orbell talked with Proactive's Stephen Gunnion about the company’s unique positioning as the only royalty company listed on AIM. He shared insights into ALT Resources' strategy, including its focus on the royalty and streaming business assets and its ambitions to grow quickly with a strong entrepreneurial team.

Orbell discussed the upcoming acquisition of a royalty from Theta Gold Mines, which will support Theta’s development of its CIL processing plant in South Africa. He said, “We expect this transaction to be accretive to our shareholders and also will allow Theta to progress in its plans.”

Orbell explained the advantages of investing in royalty and streaming companies, noting their historical outperformance against mining companies and the physical commodity. ALT Resources aims to offer exposure to both gold and critical minerals, including copper, lithium, and graphite, which align with the growth of the alternative energy economy.

He highlighted a significant market opportunity, driven by a funding gap in the mid-cap mining sector, as banks have retreated from offering competitive funding terms. Looking ahead, Orbell shared that ALT Resources is reviewing a $100 million pipeline of assets, with hopes to advance some of these opportunities within the next 12 months.

For more insights from industry leaders, make sure to visit Proactive's YouTube channel, give this video a like, subscribe, and turn on notifications to stay updated with our latest content.

#ALTResources #JamesOrbell #MiningRoyalties #ThetaGoldMines #AIMMarket #GoldInvestment #CriticalMinerals #Copper #Lithium #Graphite #Investing #ProactiveInvestors

CleanTech Lithium PLC (AIM:CTL, OTCQX:CTLHF) executive chairman Dr Steve Kesler talked with Proactive's Stephen Gunnion about the company's revised timeline for its ASX listing, aligning closely with the CEOL process for its Laguna Verde project in Chile. Kesler explained the decision to delay the listing to early 2025 to await the Chilean government's resolution on priority projects, which would allow the company to present a stronger position to potential investors in Australia.

"New potential investors in Australia have a good picture, they have the history of the company, they know where we are now with the CEOL," Kesler said. He emphasised that having the pre-feasibility study (PFS) results and updated financials in the prospectus would strengthen investor confidence in a challenging market.

Kesler also addressed the departure of the CEO designate, citing personal reasons and confirmed that CleanTech Lithium is re-engaging with other high-calibre candidates ahead of the ASX listing expected in May. Additionally, he discussed the extension of the broker retail option to 7 March, allowing more retail shareholders to participate following the successful £2.4 million interim raise.

Stay tuned to Proactive’s YouTube channel for more insights and updates. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content!

#CleanTechLithium #ASXListing #LagunaVerde #LithiumProjects #ChileMining #InvestorUpdate #CEOLProcess #PFSResults #MiningStocks #RetailInvestors

hVIVO PLC chief executive Yamin ‘Mo’ Khan tells Proactive's Stephen Gunnion about the company’s strategic acquisition of Cryostore, a specialist in temperature-controlled storage solutions for biological and clinical samples. Based in Greenwich, Cryostore enhances hVIVO’s biobank services under its hLAB banner, aligning with hVIVO's goals of expanding lab services and offering a fuller service to clients.

The acquisition, valued at up to £3.2 million, involves £2.7 million in cash and £500,000 in equity, and aims to leverage Cryostore’s established client base and regulatory certifications.

With Cryostore’s 32 freezers and nearly 3,000 square feet of storage space, hVIVO plans to integrate its existing biobank facility near Cambridge, enhancing its service offerings to clinical trial clients. The acquisition is also expected to support cross-selling opportunities within hVIVO’s clinical services and human challenge trials.

For more insightful interviews and industry updates, visit Proactive's YouTube channel. Don’t forget to like this video, subscribe to our channel, and enable notifications for future content!

#hVIVO #Cryostore #Biobank #ClinicalTrials #hLAB #MoKhan #LifeSciences #Healthcare #ProactiveInvestors #Acquisitions #Biotechnology

Alvopetro Energy CEO Corey Ruttan joined Steve Darling from Proactive to provided an update on the company’s year-end 2024 reserves and strategic outlook for 2025, highlighting its core assets in Brazil and expansion into Western Canada.

Alvopetro reported a 65% increase in 1P reserves, largely driven by the redetermination of Caburé working interests and the successful 183 A3 well at Murucututu. The company’s Caburé unit and 100% owned Murucututu asset continue to be key drivers of growth, supported by robust natural gas infrastructure and a strong gas sales agreement, with local gas prices exceeding $10 per MCF.

Looking ahead to 2025, Alvopetro has increased firm nominations to Bahia Gas by 33%, positioning itself for higher production and cash flow. The company is also advancing a new drilling campaign to convert undeveloped reserves into production, further strengthening its resource base.

Beyond Brazil, Alvopetro is making strides in Western Canada, where it has commenced its first drilling program. This marks a significant step in the company’s broader growth strategy, leveraging its expertise in natural gas development to diversify its asset portfolio and expand its international footprint.

#proactiveinvestors #alvopetroenergyltd #tsxv #alv #otcqx #alvof #OilAndGas #BrazilNaturalGas #EnergyProduction #CEOInterview #Q32024 #ProactiveInvestors

Ideal Power CEO Daniel Brdar joined Steve Darling from Proactive to discuss the company’s fourth-quarter and full-year 2024 financial results, highlighting significant progress in its B-TRAN® technology and growth strategy for 2025.

Brdar emphasized that Ideal Power’s first design win for B-TRAN® in solid-state circuit breakers (SSCBs) marks a critical milestone, validating the technology’s potential and setting the stage for a revenue ramp beginning in the second half of 2025. Based on customer projections, the initial B-TRAN®-enabled product could generate hundreds of thousands of dollars in revenue in its first year, with the potential to exceed $1 million in the second year. The company anticipates that its OEM partner will expand its SSCB offerings, further increasing revenue opportunities. He shared that a recent program review with Stellantis delivered positive feedback, opening the door to a new program focused on EV contactors.

Beyond this initial success, Ideal Power aims to secure additional SSCB design wins with major customers in the coming months, driving long-term value creation. Additionally, the company reported a multi-unit order for its SymCool® IQ intelligent power module, targeting the fast-growing renewable energy, energy storage, and EV charging markets.

Looking ahead, key catalysts for 2025 include, completing key deliverables for its first design win in the first half of the year, capturing additional design wins and securing new custom development agreements. The company will also initiate a revenue ramp in the second half of 2025 while also enhancing product capabilities, including increasing the current rating of its B-TRAN® technology.

#proactiveinvestors #idealpowerinc #nasdaq #ipwr #EVTechnology #DanielBrdar #Stellantis #SemiconductorInnovation #SymCool #ElectricVehicles #BTRAN #EnergyStorage #ProactiveInvestors

archTIS Chief Operating Officer and Kurt Mueffelmann joined Steve Darling from Proactive’s OTC studio in New York City to discuss the company’s strategic expansion and advanced data security solutions. archTIS focuses on protecting sensitive data and documents, ensuring that even if systems are compromised, critical information remains secure—a growing concern in today’s geopolitical landscape.

A key highlight is the company’s indicative offer to acquire Direktive, adding advanced technology orchestration to its portfolio. This move strengthens defenses against AI-related threats, including risks from ChatGPT and Copilot, by safeguarding intellectual property and sensitive documents from unintended public exposure.

archTIS is expanding beyond its successful engagements with the Australian Ministry of Defense, targeting growth in the U.S. and international markets. The company is pursuing contracts with the U.S. Department of Defense, NATO, and coalition forces, aiming to establish itself as a leader in military-grade data security.

Additionally, archTIS’s OTC Market listing in 2021 has increased its visibility among U.S. investors, creating new opportunities for growth. Mueffelmann emphasized that this listing is helping attract investors with deep technology sector expertise, supporting the company’s long-term vision for secure, scalable data protection.

#proactiveinvestors #archtis #otcqb #arhlf #asx #ar9 DataSecurity #CyberSecurity #KurtMueffelmann #DirektiveAcquisition #AIProtection #DefenseTechnology #USMarketExpansion #OTCMarkets #ProactiveInvestors

D3 Energy Managing Director David Casey joined Steve Darling from Proactive’s OTC studio in New York City to announce the company has been granted three new Technical Cooperation Permits (TCPs) adjacent to its flagship exploration permit, ER315. The newly acquired permits—TCP258, TCP259, and TCP260—cover a combined area of 5,797 hectares, expanding D3 Energy’s contiguous exploration footprint in South Africa’s Free State Province, a globally significant helium exploration region.

Casey highlighted that the permits provide additional low-cost exploration and appraisal opportunities. The TCPs, valid for one year, involve minimal-cost desktop studies, after which D3 Energy may apply for full Exploration Rights. These permits are expected to contribute to the company’s growing helium and methane Contingent and Prospective Resource estimates in ER315.

Meanwhile, appraisal work at ER315 continues to deliver promising results. The production testing program has recorded an average gas flow rate of 102 Mscfd over the first seven days of a 14-day test period, with gas samples analyzed by a SANAS-accredited laboratory. Preliminary results confirmed helium concentrations of 5.6% and methane levels at 83.2%, reinforcing the asset’s potential as a major helium and natural gas resource.

These results follow the recent testing at RBD01, which demonstrated world-class helium concentrations of 6.2% and provided critical insights into the reservoir’s deliverability. The success at Nooitgedacht Major further underscores the broader prospectivity of the asset, positioning D3 Energy as a key player in the emerging helium market.

#proactiveinvestors #d3energy #otcqb #dnrgf #asx #d3e #HeliumExploration #SouthAfrica #NaturalGas #EnergySector #DavidCasey #ProactiveInvestors #USMarket #ASX #OTCMarkets